Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jazz Pharmaceuticals IPO Will Fund Luvox CR Commercialization

Executive Summary

Jazz Pharmaceuticals is hoping to raise more than $100 million through its initial public offering to help fund the commercialization of its lead compound, Luvox CR (see chart: "1Jazz Pharmaceuticals IPO")

You may also be interested in...



It's Fusion As Jazz Pharmaceuticals, Azur Pharma Reach Merger Agreement

The maker of narcolepsy drug Xyrem gets a portfolio of CNS and women's health drugs while moving its headquarters to Ireland, saving millions on taxes.

Sales Rep “Ride Alongs” Required As Part Of Jazz’s Xyrem Settlement

Jazz Pharmaceuticals' sales reps will have limited opportunities for improvisation under a corporate integrity agreement signed to settle charges of off-label detailing of Xyrem (gamma-hydroxybutyrate)

Sales Rep “Ride Alongs” Required As Part Of Jazz’s Xyrem Settlement

Jazz Pharmaceuticals' sales reps will have limited opportunities for improvisation under a corporate integrity agreement signed to settle charges of off-label detailing of Xyrem (gamma-hydroxybutyrate)

UsernamePublicRestriction

Register

PS048468

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel